DRA Consultants (540144)
Slow GrowerScore breakdown: P/E: 3/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹47.25 |
| Market Cap | ₹53.59 Cr |
| P/E Ratio | 6.6 |
| ROCE | 11.69% |
| ROE | —% |
| Dividend Yield | 0% |
| Profit Growth | -2.02% |
| Debt/Equity | — |
| Sales Growth | 3.73% |
| 52-Week Range | ₹11.55 — ₹47.25 |
| Sector | Commercial Services & Supplies |
Strengths
- P/E of 6.60 gives an earnings yield of roughly 15% if current profitability is sustainable.
- ROCE of 11.69% indicates reasonably efficient use of capital for a small consultancy.
- Latest quarter shows ₹9 Cr sales with ₹1 Cr net profit, implying a healthy ~11% net margin.
- Sales still grew 3.73% despite a small profit decline, showing modest business resilience.
Concerns
- Profit growth is negative at -2.02%, and revenue growth of only 3.73% means limited compounding.
- Piotroski F-Score of 4/9 suggests weak financial health and possible red flags in operations.
- Zero dividend yield means investors get no income while waiting for growth.
- Critical data — book value, ROE, debt/equity, and promoter holding — is unavailable, preventing a complete margin-of-safety analysis.
- Stock has moved from ₹11.55 to ₹47.25 in 52 weeks while profits fell, raising sentiment risk.
AI Analysis
At ₹47.25, DRA Consultants has a market cap of only ₹54 Cr and a trailing P/E of 6.60. On the surface, that looks like the sort of cigar-butt Graham might examine. But a value investor must first ask: what is the earning power, and how durable is it? The latest quarter shows ₹9 Cr of sales and ₹1 Cr of net profit, while the broader figures show sales growth of just 3.73% and profit declining 2.02%. That is not a compounding machine. In fact, over the last year the stock has raced from ₹11.55 to ₹47.25, while underlying profits fell. Mr. Market has become enthusiastic, but I remain wary. ROCE of 11.69% is acceptable, but not exceptional, and with zero dividend yield, the shareholder relies entirely on price appreciation. The Piotroski F-Score of 4/9 confirms weak financial health; this is not a pristine balance sheet. I also notice PEG of 1.77, which suggests that on a growth-adjusted basis the stock is not as cheap as the P/E alone implies. There are serious information gaps — book value, ROE, debt-equity, and promoter holding are unavailable. Graham would insist on knowing the asset backing and whether promoters have skin in the game. Without those, I cannot value the business with confidence. All I can say is this is a slow-growing, small consultancy with modest profitability and a low headline multiple. It might be a takeover candidate or a turnaround, but there's no evidence in the figures. In Buffett's words, 'It's far better to buy a wonderful company at a fair price than a fair company at a wonderful price.' DRA appears to be a fair-company-at-wonderful-price candidate at best, and the price may already reflect everything good. I would wait for more data and a margin of safety.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer